NEW YORK (GenomeWeb News) – The pharmaceutical firm Janssen R&D has teamed up with the Multiple Myeloma Research Foundation to help MMRF and its partners pursue their Personalized Medicine Initiative, part of which is a large clinical and molecular profiling study.

MMRF said today that Janssen has joined its pre-competitive consortium, a group of partners that support the PMI and its Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile, or CoMMpass, program. The PCC partners provide both scientific and financial support for the initiative.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.